SLC5A2 and chronic kidney disease: In recent years, cardiorenal protection studies have made significant progress in patients with CKD, and the introduction of sodium-glucose cotransporter protein 2 (SGLT2) inhibitors in particular has provided an important new tool in the treatment of CKD (1, 2).